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Abstract Women are increasingly delaying conception to later years. Hormonal contraception induces artiﬁcial cyclicity, which does
not, like natural cyclicity, reﬂect normal, physiological ovarian behaviour. Therefore, long-term users of hormonal contraceptives,
in particular, fail to derive potential diagnostic beneﬁts from changes in menstrual cyclicity, which usually alerts patients and phy-
sicians to developing ovarian pathology. Timely diagnosis of ovarian problems is further hampered, as anti-Müllerian hormone is
suppressed by hormonal contraceptives, making the accurate assessment of functional ovarian reserve more difﬁcult. Women on long-
term hormonal contraceptives who develop premature ovarian senescence at young ages, therefore, often go undiagnosed until ter-
mination of hormonal contraception, when they present with either post-contraception amenorrhea, other menstrual abnormalities
or infertility. As evolving screening options now permit the detection of young women at risk for premature ovarian senescence, it
is proposed that young women are offered ‘risk screening’ for premature ovarian senescence before starting long-term hormonal
contraception. A potential protocol is outlined.
© 2014 Reproductive Healthcare Ltd. Published by Elsevier Ltd.
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Introduction
A life span approach to health promotion and disease pre-
vention has been taken to improve maternal, infant and child
health (Johnson et al., 2006a). The main focus of precon-
ception health initiatives has been to encourage every woman
to develop a reproductive life plan. As a result, family plan-
ning services in the USA have substantially increased in
availability.
Paradoxically, a rapidly growing problem arising from im-
proved family planning services is age-related subfertility.
Long-term contraceptive use has become common practice,
as current hormonal contraceptives are safe and do not nega-
tively affect later pregnancy chances. There is a widely held
perception, however, that all it takes to conceive after pro-
longed contraceptive use is to terminate such treatments.
While this may be true for many women, it does not apply
to women who quietly develop premature ovarian senes-
cence during years of contraceptive use.
About 10% of women develop premature ovarian senes-
cence, a majority (9%) in the form of premature ovarian aging
(POA), also called occult primary ovarian insufﬁciency. About
1% of women develop premature ovarian failure, also called
primary ovarian insufﬁciency (Gleicher et al., 2009). Both of
these patient populations will be unaffected by premature
ovarian senescence while on hormonal contraceptives. In most
cases, a ﬁrst sign would be post-contraception amenor-
rhoea, menstrual abnormalities or infertility upon cessation
of hormonal contraception.
Women who are aware of their risk of developing prema-
ture ovarian senescence may choose a non-hormonal form of
contraception. At minimum, they should schedule interrup-
tions in their contraceptive schedules, which would allow
proper assessments of their functional ovarian reserve (FOR),
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as hormonal contraceptives reduce the diagnostic accuracy
of assessing FOR (Dolleman et al., 2013).
As 10% of women are at risk for premature ovarian senes-
cence, a new paradigm of offering young women FOR assess-
ments before starting hormonal contraception during routine
family planning is proposed. Accompanied by proper coun-
selling, this new paradigm may or may not improve women’s
autonomy over their reproductive health.
Evaluation of FOR has become clinically routine in infer-
tile women, and a variety of tests are available for that
purpose (Johnson et al., 2006b). In young women, who for
various reasons choose to delay pregnancy, screening of FOR
has neither entered clinical practice nor been raised in policy
recommendations of professional organizations. The Ameri-
can Society for Reproductive Medicine offers a patient booklet
and a committee opinion describing natural fertility decline
that begins in the early 30s (American Society for Reproductive
Medicine 2012; 2014); however, no professional society guide-
lines are available on this type of counselling before start-
ing contraception or during routine well-woman visits.
Simple tests can be carried out to assess risk before start-
ing hormonal contraceptives. Anti-Müllerian hormone (AMH)
is the test of choice for assessing FOR, as normal age-
speciﬁc ovarian reserve parameters have been established for
this hormone (Kelsey et al., 2011). These are speciﬁc enough
to determine whether a young woman is within age-speciﬁc
appropriate range of AMH, in potential longitudinal follow up,
or both, and whether she should stay on her age-speciﬁc AMH
curve or deviate. Women destined to develop POA will pro-
gressively deviate towards lower age-speciﬁc AMH ranges. Im-
portant limitations of AMH testing include the stability of the
current assay and inﬂuence of body mass index, ethnicity,
smoking and a lack of an association between AMH and fer-
tility in young women. Despite these limitations, AMH re-
ﬂects the size of the pool of antral follicles, representing the
quantity of the remaining primordial follicles, which corre-
lates with the remaining length of reproductive lifespan (Broer
et al., 2014).
As with AMH, age-speciﬁc FSH levels have been estab-
lished, and can further help in evaluating FOR. Different mu-
tations of the FMR1 gene have recently been described as
predictive of ovarian ageing patterns (Gleicher et al., 2010).
All three tests are routinely available from commercial
laboratories.
A potential algorithm to deﬁne women at risk for prema-
ture ovarian senescence before startging long-term hor-
monal contraceptives is presented in Figure 1. Women
identiﬁed as potentially at risk may be advised to abstain from
using long-term-hormonal contraceptives, thereby permit-
ting longitudinal follow up of age-speciﬁc AMH and FSH until
a deﬁnite diagnosis of POA is reached or refuted.
Such an algorithm can be integrated into routine family
or primary gynaecology practice, where AMH, FSH levels and
FMR1 testing can be obtained in association with routine family
planning counselling sessions. If initially observed AMH, FSH,
or both, are in midrange for age, the likelihood of increased
risk towards premature ovarian senescence is low. Devia-
tions from age-speciﬁc mid-range, however, are indicative of
risk. They then can be either conﬁrmed or refuted with serial
AMH, FSH observations, or both. If deviations from age-
speciﬁc mid-range increase over time, a diagnosis of POA
becomes likely. A diagnosis can be considered established once
AMH, FSH levels, or both, are outside age-speciﬁc range (95%
conﬁdence interval) (Barad et al., 2007; Kelsey et al., 2011).
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Figure 1 Potential screening scheme for assessment of functional ovarian reserve before starting hormonal contraceptives.
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Suspicion, likelihood or conﬁrmation of low FOR may be con-
sidered relative contraindications to hormonal contracep-
tives, as they prohibit continuous observation of FOR and,
indeed, further depress AMH (Dolleman et al., 2013).
Detection of abnormally high levels of AMH, as a second-
ary beneﬁt from this kind of screening, offers the potential
of early diagnosis of polycystic ovary syndrome (PCOS) (Pigny
et al., 2006) and associated metabolic syndrome risk. Diag-
nosis of PCOS before prescribing hormonal contraceptives then
also allows the selection of hormonal contraceptives with low
androgen indices. Routine surveillance of AMH in women with
PCOS is generally not indicated; however, early diagnosis of
PCOS may also have relevance for women with the FMR1 sub-
genotype het-norm/low, which has been associated with a
PCOS-like ovarian phenotype at young age, which quickly de-
pletes ovarian reserve. By middle age, AMH is therefore often
associated with abnormally low FOR (Gleicher et al., 2010).
In low-risk populations, any screening programmewill result
in false positive and false negative results. Both can lead to
unnecessary interventions, which may result in harm to those
individuals. In the case of false negative and even normal FOR
testing, women may be falsely reassured that their decision
to delay fertility is without future risk. Further delaying child-
bearing may worsen the situation. In the case of falsely low
FOR testing, young women may pursue unnecessary medical
investigations, fertility preservation or even pregnancy before
establishing a stable environment in which to raise the re-
sulting child. These potential risks, however, can be miti-
gated through appropriate patient counselling before testing
and in follow-up care. Clinical data supporting such an algo-
rithm are currently lacking; therefore, research is needed in
several crucial areas to support its wide implementation. These
include prospective longitudinal studies of ovarian reserve in
individuals taking hormonal contraception and those are who
are not; pilot studies of women at risk (i.e. those with a family
history of primary ovarian insufﬁciency or autoimmunity); and
appropriate cost-beneﬁt analysis incorporating costs of screen-
ing and interventions, including the burden of delayed fer-
tility and infertility care.
Counselling on reproductive ageing, and giving young
women the chance to prospectively assess their risk for pre-
mature ovarian senescence as part of routine family plan-
ning and gynaecology visits will permit women to formulate
an informed reproductive life plan, including earlier than
otherwise planned conceptions or oocyte or embryo
cryopreservation (fertility preservation). Whatever the ﬁnal
resolution, it will likely be more successful and cost-effective
than the same decision reached at more advanced ages. The
family planning paradigm propsed here, therefore, may enable
women to formulate an informed reproductive life plan that
can result in improved maternal and child health.
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